Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant
Open Access
- 19 December 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (12) , e0208345
Abstract
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that the ability of an epitope to elicit effective humoral immunity depends on its exposure on the virion, we have used a reverse genetics approach to select variants from an HIV-1 AC10_29 randomly mutated envelope library that showed increased affinity for a selected bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were analyzed by deep-sequencing showing a small number of dominant changes, including the loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accordingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs 4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the amino acids specific for the selected variant are associated with an increased sensitivity for 4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29 env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detectable neutralizing activity in immunized rabbits, one animal showed antibody response to the 4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV envelope immunogen sequences that direct antibody responses to specific envelope regions.Keywords
Funding Information
- Comisión Nacional de Investigación Científica y Tecnológia. Chile
- Fundação para a Ciência e a Tecnologia
- Secretaría de Estado de Investigación, Desarrollo e Innovación
- European Regional Development Fund (CTQ2015-63919-R)
- HIVACAT program
- HIVACAT program
- HIVACAT program
- HIVACAT program
- HIVACAT program
- HIVACAT program
- Horizon 2020 (GA681137)
- Red de Investigación en SIDA (RD16/0025/0014)
- Horizon 2020 (731626)
- Horizon 2020 (SAF2015-66193-R)
- FIPSE (36780/80)
- Ministerio de Ciencia y Tecnología (RYC-2007-00788)
- INNPACTO (IP-2012-0325-010000)
- Red de Investigación en SIDA (RD12/0017/0001)
- Horizon 2020 (681032)
- Horizon 2020 (681032)
This publication has 83 references indexed in Scilit:
- Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoProceedings of the National Academy of Sciences, 2012
- Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Nature, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- Antibody-based protection against HIV infection by vectored immunoprophylaxisNature, 2011
- Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimerProceedings of the National Academy of Sciences, 2011
- Efficient Identification of Human Immunodeficiency Virus Type 1 Mutants Resistant to a Protease Inhibitor by Using a Random Mutant LibraryAntimicrobial Agents and Chemotherapy, 2011
- Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16Journal of Virology, 2010
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Autoreactivity in Human IgG+ Memory B CellsImmunity, 2007
- Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization SensitivityJournal of Virology, 2006